The U.S. Food and Drug Administration has officially confirmed a nationwide shortage of estrogen-based hormonal patches, signaling a supply constraint that affects patients across Idaho and the broader Mountain West.
Why It Matters
Estradiol transdermal patches are a primary treatment for menopause symptoms, including hot flashes, night sweats, insomnia, and bone density loss. The National Institute on Aging notes that menopause typically occurs between ages 45 and 55. For Idaho women in this demographic, the shortage complicates access to hormone replacement therapy.
The supply issue coincides with a broader legislative push for menopause support. As of May, more than 60 pieces of menopause-related legislation were introduced nationwide, and 26 states have enacted related laws since 2019. Idaho lawmakers have also focused on healthcare access, recently preparing to enforce Medicaid work rules for 85,000 enrollees and mapping opioid settlement spending toward vulnerable counties.
What Happened
The FDA released a statement earlier this month acknowledging the deficit. This marks the first time the agency has listed estradiol patches on its official shortage list. The American Society of Health-System Pharmacists had identified the shortage as early as January, but the FDA did not include the patches in its shortage report at that time.
The regulatory landscape for these patches shifted recently. The FDA removed estradiol patches from its “black box” warning status two months prior to January. This change likely contributed to increased prescribing and subsequent demand.
By The Numbers
- Six manufacturers are currently working to expand capacity and prioritize production of the patches.
- More than 60 menopause-related bills were introduced nationwide as of May.
- 26 states have passed menopause-related laws since 2019.
- 45 to 55 is the typical age range for menopause onset.
Zoom Out
The shortage reflects a surge in demand driven by greater public awareness of menopause treatment. Stateline reported in May that this awareness led states to introduce legislation for insurance coverage and workplace accommodations. The National Menopause Foundation provided data supporting these trends during the same period.
Federal regulators are responding to the market pressure. The FDA stated it is expediting actions to increase supply. All six manufacturers involved in patch production are working to expand capacity. The agency emphasized that it views increased interest in menopause treatment as an important development for women’s health.
What’s Next
The FDA indicated it is working closely with manufacturers to ensure supply keeps pace with demand. Legislative activity is expected to continue, with more bills anticipated in the 2027 sessions. Idaho patients may see improved availability as production scales up, though immediate access remains constrained.
About the Author
